insights_auto
Kāpēc uzņēmuma ALNOV akciju cena ir pieaugusi 2,93%?
Atklājiet vairāk iespējuchevron_right
ALNOV:EPA
Novacyt SA
0,42 €
arrow_upward
+2,93%(+0,012) 1 d.
9. nov., 17:35:27 GMT+1 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: ALNOV…
Atvērt
0,41 €
Augsta
0,43 €
Zema
0,41 €
Tirgus kapitalizācija
31,34 milj.
Vid. apjoms
174,97 tūkst.
Apjoms
77,13 tūkst.
Augstākā 52 ned.
1,04 €
Zemākā 52 ned.
0,29 €
Peļņa uz vienu akciju
-0,38 €
Apgrozībā esošās akcijas
72,59 milj.
Darbinieku skaits
228
Atvērt
0,41 €
Augsta
0,43 €
Zema
0,41 €
Tirgus kapitalizācija
31,34 milj.
Vid. apjoms
174,97 tūkst.
Apjoms
77,13 tūkst.
Augstākā 52 ned.
1,04 €
Zemākā 52 ned.
0,29 €
Peļņa uz vienu akciju
-0,38 €
Apgrozībā esošās akcijas
72,59 milj.
Darbinieku skaits
228
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
FinancialContent
·
pirms 56 minūtēm
Tidewater (NYSE:TDW) posts better-than-expected sales in Q3 2026
Quantisnow
·
pirms 5 minūtēm
Citigroup (C): Citi registers floating rate notes due November 2031 on NYSE
Yahoo Finance
·
pirms 1 stundas
The Trade Desk (NASDAQ:TTD) beats expectations in strong Q3 2026, stock jumps 21.8%
MarketWatch
·
pirms 51 minūtes
Dow sees its third 1,000-point swing in four days. Why the volatility isn’t over yet.
Profils
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Par “Novacyt SA”
ĢenerāldirektorsDavid Allmond
Darbinieki228
Dibināšanas datums2006. gada 3. jūl.
Galvenais birojs-
SektorsHealth Care
Nozare-
Tīmekļa vietnenovacyt.com